Identification of drug targets and mechanism of action of epigenetic modulators in musculoskeletal inflammation and oncology
The aim of our group is to understand pathogenic epigenetic mechanisms in a variety of musculoskeletal diseases, comprising inflammatory (eg autoimmune diseases) and malignant processes (eg bone cancer) and stem cells (eg mesenchymal and haematopoietic). We are positioned to investigate this effectively via
(1) excellent interactions with clinical colleagues, and
(2) through collaboration with the Structural Genomics Consortium (SGC), an international public-private partnership, to develop and evaluate unique small molecule inhibitors to probe biological functions of epigenetic targets in a disease context.
Several aspects of molecular biology techniques are established in the group, and comprise cell culture (primary, continuous cell lines), protein purification and characterisation, various types of assays (including enzyme, apoptosis, proliferation), flow and mass cytometry, next generation sequencing and data analysis. Other skill sets such as presentation and communication abilities, team working and multi-tasking are important parameters for success. It is expected that any candidate will be successfully acquiring any of these skill sets, depending on their training needs.
- Tumber A, Nuzzi A, Hookway ES, Hatch SB, Velupillai S, Johansson C, Kawamura A, Savitsky P, Yapp C, Szykowska A, Wu N, Bountra C, Strain-Damerell C, Burgess-Brown NA, Ruda GF, Fedorov O, Munro S, England KS, Nowak RP, Schofield CJ, La Thangue NB, Pawlyn C, Davies F, Morgan G, Athanasou N, Müller S, Oppermann U, Brennan PE. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. Cell Chem Biol. 2017 Mar 16;24(3):371-380. doi: 10.1016/j.chembiol.2017.02.006. Epub 2017 Mar 2. PubMed PMID: 28262558; PubMed Central PMCID: PMC5361737.
- Nowak RP, Tumber A, Johansson C, Che KH, Brennan P, Owen D, Oppermann U. Advances and challenges in understanding histone demethylase biology. Curr Opin Chem Biol. 2016 Aug;33:151-9. doi: 10.1016/j.cbpa.2016.06.021. Epub 2016 Jun 29. Review. PubMed PMID: 27371875.
- Johansson C, Velupillai S, Tumber A, Szykowska A, Hookway ES, Nowak RP,Strain-Damerell C, Gileadi C, Philpott M, Burgess-Brown N, Wu N, Kopec J, Nuzzi A, Steuber H, Egner U, Badock V, Munro S, LaThangue NB, Westaway S, Brown J, Athanasou N, Prinjha R, Brennan PE, Oppermann U. Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nature Chem Biol. 2016 Jul;12(7):539-45. doi: 10.1038/nchembio.2087. Epub 2016 May 23. PubMed PMID: 27214403.
- Carbonneau M, M Gagné L, Lalonde ME, Germain MA, Motorina A, Guiot MC, Secco B, Vincent EE, Tumber A, Hulea L, Bergeman J, Oppermann U, Jones RG, Laplante M, Topisirovic I, Petrecca K, Huot MÉ, Mallette FA. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nature Commun. 2016 Sep 14;7:12700. doi: 10.1038/ncomms12700. PubMed PMID: 27624942; PubMed Central PMCID: PMC5027283.
- Johansson C, Tumber A, Che K, Cain P, Nowak R, Gileadi C, Oppermann U. The roles of Jumonji-type oxygenases in human disease. Epigenomics. 2014 Feb;6(1):89-120. doi: 10.2217/epi.13.79. Review. PubMed PMID: 24579949; PubMed Central PMCID: PMC4233403.